Instacart, DispatchHealth launch joint effort to mitigate food insecurity

A grocery-delivery giant is partnering with a commercial provider of medical house calls to bring healthy meals to patients in their homes.

Instacart and DispatchHealth announced their collaboration Jan. 23, describing their goal as reducing the impact of food insecurity on individuals’ wellness, and with it, on population-level healthcare costs.

Through the program, DispatchHealth clinicians will have access to the “platform, products and partnerships” of Instacart Health. The caregivers will offer their patients food stipends and medically tailored shopping lists. They’ll also be able to send food straight to patients’ doors with speed and accuracy, “which could help boost adherence rates,” according to the announcement.

DispatchHealth CMO Phil Mitchell, MD, says patients’ wellbeing is “closely tied to their environment, and we witness firsthand how social determinants like nutritional accessibility affect their overall health.”

Instacart Health VP and GM Sarah Mastrorocco add that the partnership will help ensure that DispatchHealth patients “can get the essentials they need delivered from the local retailers they trust.”

Denver-based DispatchHealth was founded in 2013 and operates in 21 states. Instacart is headquartered in San Francisco, employs around 3,500 and is worth around $10 billion.  

Full announcement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.